Abstract
Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 698-703 |
| Number of pages | 6 |
| Journal | Transplant International |
| Volume | 23 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Hepatocellular carcinoma
- Image-guided ablation
- Molecular targeted therapies
- Transarterial chemoembolization
ASJC Scopus subject areas
- Transplantation
- Medicine(all)
Cite this
Loco-regional interventional treatment of hepatocellular carcinoma : Techniques, outcomes, and future prospects. / Lencioni, Riccardo; Crocetti, Laura; De Simone, Paolo; Filipponi, Franco.
In: Transplant International, Vol. 23, No. 7, 2010, p. 698-703.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Loco-regional interventional treatment of hepatocellular carcinoma
T2 - Techniques, outcomes, and future prospects
AU - Lencioni, Riccardo
AU - Crocetti, Laura
AU - De Simone, Paolo
AU - Filipponi, Franco
PY - 2010
Y1 - 2010
N2 - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.
AB - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and safety profile of TACE compared with conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.
KW - Hepatocellular carcinoma
KW - Image-guided ablation
KW - Molecular targeted therapies
KW - Transarterial chemoembolization
UR - http://www.scopus.com/inward/record.url?scp=77953184336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953184336&partnerID=8YFLogxK
U2 - 10.1111/j.1432-2277.2010.01109.x
DO - 10.1111/j.1432-2277.2010.01109.x
M3 - Article
C2 - 20492618
AN - SCOPUS:77953184336
VL - 23
SP - 698
EP - 703
JO - Transplant International
JF - Transplant International
SN - 0934-0874
IS - 7
ER -